New blood test could help spot aggressive prostate cancer earlier

For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and suddenly the room gets smaller. There may be more blood work, an MRI, a biopsy, waiting, worry, and the hard question every man wants answered fast: is this a dangerous cancer, or is this an alarm bell ringing for something less serious?

The American Cancer Society estimates 333,830 new prostate cancer cases and 36,320 deaths in the U.S. in 2026, so the question is not rare. It sits in exam rooms across the country every week.

That is why a new generation of blood tests is drawing attention. Tools such as Stockholm3, IsoPSA, and AI-powered panels like ClarityDX Prostate are trying to do something the standard PSA test has struggled to do on its own: separate aggressive cancers from slower, lower-risk disease. The aim is not simply to find more cancer. It is to find the cancers that need to be found.

The PSA Test Opened the Door, but the Signal Can Be Blurry

The PSA test measures prostate-specific antigen in the blood. It has helped doctors catch prostate cancer earlier for years, but it can also raise alarms for reasons that have nothing to do with a dangerous tumor. Benign prostate enlargement, infection, inflammation, and age can all push PSA higher. That means some men end up facing biopsies that do not find cancer.

The debate has never been simple. A 2026 Cochrane review found PSA screening modestly reduces prostate cancer deaths by about 2 per 1,000 men screened, while about 500 men must be invited to screening to prevent one prostate cancer death.

That benefit matters. So do the harms: false positives, anxiety, overdiagnosis, and treatment for tumors that may never have threatened a man’s life. PSA opened the door. The next tests are trying to show doctors which door is worth walking through.

The Real Goal Is Finding the Right Cancer

Not every prostate cancer behaves the same way. Some grow slowly and may be watched over time. Others are aggressive and need faster treatment. That difference is the heart of modern prostate cancer screening.

The American Cancer Society reported that prostate cancer incidence rose 3% per year from 2014 through 2022 after years of declining diagnoses. SEER data also show that prostate cancer is more common in older men, men with a family history, and non-Hispanic Black men.

For most, the question is not just “Do I have cancer?” It is “Do I have the kind that could hurt me if we wait?”

That is the promise behind the new tests. They add more clues to the blood draw, including proteins, genetic markers, hormone patterns, and clinical details. The result is a fuller risk profile, not just one number carrying too much weight.

Stockholm3 Builds a Smarter Risk Score

Stockholm3, developed with researchers at Sweden’s Karolinska Institutet, combines blood protein markers, genetic markers, and clinical information such as age and family history. In a large population-based study involving 12,670 men ages 50 to 74, Karolinska reported that Stockholm3 detected 90% of aggressive prostate cancer cases, compared with 74% for PSA.

Thorgerdur Palsdottir, a researcher at Karolinska Institutet, put the challenge plainly: “The major challenge in prostate cancer screening is not just to find more cancer cases, but to identify the cancers that are truly dangerous.” She also said the results showed that Stockholm3 identified more aggressive cases than PSA, “without increasing the number of unnecessary follow-ups.”

That is the kind of shift doctors want: a test that does not simply shout louder, but speaks more clearly.

IsoPSA Looks at the Shape of PSA, Not Just the Amount

IsoPSA takes a different approach. Standard PSA testing measures the amount of PSA in the blood. IsoPSA looks at structural changes in the PSA protein that may be linked with high-grade prostate cancer.

The FDA’s premarket approval database indicates that IsoPSA was approved on November 28, 2025, for use with other patient information in men 50 and older with total PSA levels from 4.0 to 10.0 ng/mL when a biopsy is already being considered.

That last part matters. IsoPSA is not a stand-alone diagnosis. The FDA states that a prostate biopsy is required to diagnose cancer. Its role is to help doctors and patients decide how risky the situation looks before moving forward.

Eric A. Klein, MD, Emeritus Chair of Cleveland Clinic’s Glickman Urological & Kidney Institute, said FDA approval “underscores the value and clinical utility of IsoPSA in distinguishing benign elevations of PSA from those due to high grade cancer.” For men stuck between worry and biopsy, that distinction can carry real emotional weight.

AI-Powered Panels Add Another Layer

ClarityDX Prostate uses machine learning to combine PSA, other blood-based markers, and clinical details into a risk score. A 2024 Nature Digital Medicine study built the tool from a 3,448-patient cohort and reported 95% sensitivity, 35% specificity, 54% positive predictive value, and 91% negative predictive value for high-risk cancer in the validation group at a 25% risk threshold.

That does not mean the test is “95% accurate” in every setting. Sensitivity means it was strong at flagging many men with higher-risk disease in that study. Specificity was lower, meaning false alarms can still occur. The same study found that using the test at that threshold could avoid up to 35% of unnecessary biopsies.

M. Eric Hyndman, MD, PhD, FRCSC, a urologist at the Southern Alberta Institute of Urology and chief medical officer at Nanostics, said the study showed ClarityDX Prostate was accurate at predicting grade group 2 and above prostate cancer. He said using it after PSA screening could give doctors more information to decide if a biopsy is needed.

The Next Frontier Goes Beyond PSA

Researchers are also looking at hormones, circulating tumor cells, tumor DNA, and other blood markers that may help better characterize prostate cancer behavior.

Aggressive prostate cancer was linked with lower androstenedione, lower DHEA-S, lower free PSA percentage, and higher sex hormone-binding globulin. Combining those markers with clinical details improved prediction compared with PSA-only approaches.

At Dana-Farber Cancer Institute, researchers developed a blood test called NEMO to help distinguish a dangerous advanced subtype called neuroendocrine prostate cancer from more common prostate adenocarcinoma.

Dr. Himisha Beltran said, “We hope this blood test can be used to determine if a patient is developing neuroendocrine prostate cancer.” That is not routine screening for the average man. It is a sign of where the science is going: toward reading cancer biology in more detail from the blood.

What Men and Families Should Take From This

The new message is not that PSA is useless. It is possible that PSA may soon have more help. The CDC, in line with the U.S. Preventive Services Task Force, says men ages 55 to 69 should make individual screening decisions after talking with a clinician, while men 70 and older are not advised to receive routine PSA screening.

The American Urological Association also supports shared decision-making and recommends repeating a newly elevated PSA before considering secondary biomarkers, imaging, or biopsy.

That means the next era of screening may feel less like a single red flag and more like a conversation. A man with an elevated PSA may have more options before biopsy. A doctor may have more tools to judge risk. A family may get clearer language around the question that matters most: is this the kind of cancer that needs action now?

The promise is real, but caution belongs in the same room. Access, cost, insurance coverage, test availability, and performance across diverse populations still matter. A better blood test does not replace medical judgment, imaging, pathology, or a biopsy when needed.

Still, the direction is meaningful. For years, prostate cancer screening has asked men to live with gray areas. These new tests may not remove every uncertainty, but they could make the gray less foggy. One vial of blood may never tell the whole story. It may soon help doctors read the danger more clearly.

Disclaimer – This list is solely the author’s opinion based on research and publicly available information. It is not intended to be professional advice.

Like our content? Be sure to follow us